FDA Guidance Document: Immunogenicity Assessment for Therapeutic Protein Products

This FDA guidance provides a framework for predicting, detecting, and managing the risk of unwanted immune responses to therapeutic protein products. Such responses, leading to anti-drug antibodies (ADAs), can neutralize drug activity, alter pharmacokinetics, or cause serious adverse events.

Applies broadly to therapeutic protein products such as mAbs, cytokines, and enzymes from early nonclinical development through clinical trials and post-marketing.

Core Principle
Immunogenicity risk assessment is multidisciplinary, science- and risk-based, and must consider factors related to:

• The product structure, formulation, process impurities, aggregation.

• The patient  immune status, disease type, genetics, concomitant therapies.

• The clinical regimen  route, dose, frequency, treatment duration.

Key Elements

1. Risk Assessment Early evaluation of all known risk factors, updated throughout development.

2. Tiered Bioanalytical Strategy

   • Screening assay (sensitive detection of ADAs)

   • Confirmatory assay (specificity check)

   • Titer assay (quantitation)

   • Neutralizing antibody assay (functional impact)Each tier must follow validated assay principles with pre-defined cut-points, sensitivity, and specificity criteria.

3. Clinical Impact Evaluation Evaluation must include longitudinal correlation of ADA/NAb results with PK/PD, efficacy, and safety, and inform risk categorization

4. Nonclinical Studies Useful for mechanistic understanding, but limited in predicting human immunogenicity, and generally cannot be used to predict incidence or clinical impact in humans

CMC’s Critical Role
Many immunogenicity risks originate from product quality attributes, making CMC central to mitigation:

• Aggregation control — prevent aggregate formation via formulation and process design.

• Impurity removal — reduce host cell proteins and other immunostimulatory contaminants.

• Structural consistency — maintain primary structure and post-translational modifications.

• Formulation/container impact — avoid excipients or leachables that increase risk.

• Comparability assessments must generate data demonstrating that changes (manufacturing, formulation, container) do not increase immunogenicity risk.